Literature DB >> 22520236

Protective effect of annexin-A1 against irreversible damage to cavernous tissue after cavernous nerve injury in the rat.

Fernando N Facio1, Arthur L Burnett.   

Abstract

UNLABELLED: Study Type - Aetiology (case control) Level of Evidence 3b. What's known on the subject? and What does the study add? Penile rehabilitation is still controversial regarding good results. Our study shows a non-invasive treatment option to recovery after cavernous nervous damage. The assessment of changes in the intracavernous pressure and karyometry demonstrates the protective effect of annexin-A1 in an animal model of cavernous nerve injury. We found that annexin-A1 effectively preserved erectile function, evidently through significantly protecting the corpus cavernosum tissue against fibrosis.
OBJECTIVE: • To evaluate the protective effect of annexin-A1 against irreversible damage to cavernous tissue after cavernous nerve injury. PATIENTS AND METHODS: • Thirty Sprague-Dawley male rats were divided into 3 groups; sham-operated rats (n= 10), bilateral cavernous nerve injury treated intravenously with 100 µg/kg annexin-A1 (n= 10), and a crush group of rats submitted to bilateral cavernous nerve injury and vehicle (n= 10). Groups were compared in respect to intracavernous pressure and karyometric parameters.
RESULTS: • After annexin-A1 treatment, the maximum changes in intracavernous pressure responses were significantly higher in the annexin-A1 group compared to the vehicle-only group on the 7(th) postoperative day (p-value <0.05). Hematoxylin-eosin staining showed that the percentage of cavernosal smooth muscle was higher in the annexin-A1 group. Karyometry showed that the nuclear volume was greater in the annexin-A1 group, as was the major/minor smooth muscle cell diameter ratio compared to the vehicle-only group on the 7(th) postoperative day (p-value <0.05).
CONCLUSION: • This is the first report that, by assessing changes in the intracavernous pressure and karyometry, demonstrates the protective effect of annexin-A1 in an animal model of cavernous nerve injury. We found that annexin-A1 effectively preserved erectile function, evidently through significantly protecting the corpus cavernosum tissue against fibrosis.
© 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22520236     DOI: 10.1111/j.1464-410X.2012.11097.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  Anti-inflammatory and anti-fibrotic effects of annexin1 on erectile function after cavernous nerve injury in rats.

Authors:  F N Facio; M F Facio; L F Spessoto; D Pessutti; L O Reis; S G Campos; S Taboga
Journal:  Int J Impot Res       Date:  2016-08-25       Impact factor: 2.896

2.  Protein targets of acrylamide adduct formation in cultured rat dopaminergic cells.

Authors:  Christopher J Martyniuk; April Feswick; Bin Fang; John M Koomen; David S Barber; Terrence Gavin; Richard M Lopachin
Journal:  Toxicol Lett       Date:  2013-04-06       Impact factor: 4.372

Review 3.  Therapeutic potential for targeting Annexin A1 in fibrotic diseases.

Authors:  Zhibin Yan; Xurui Cheng; Tao Wang; Xiangyu Hong; Gang Shao; Caiyun Fu
Journal:  Genes Dis       Date:  2022-06-18

4.  nNOS-positive minor-branches of the dorsal penile nerves is associated with erectile function in the bilateral cavernous injury model of rats.

Authors:  Yen-Lin Chen; Ting-Ting Chao; Yi-No Wu; Meng-Chuan Chen; Ying-Hung Lin; Chun-Hou Liao; Chien-Chih Wu; Kuo-Chiang Chen; Shang-Shing P Chou; Han-Sun Chiang
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

5.  Intracavernous Injection of Platelet-Rich Plasma Therapy Enhances Erectile Function and Decreases the Mortality Rate in Streptozotocin-Induced Diabetic Rats.

Authors:  Chun-Hou Liao; Kau-Han Lee; Shiu-Dong Chung; Kuo-Chiang Chen; Chellappan Praveen Rajneesh; Bo-He Chen; Jai-Hong Cheng; Wang-Ying Lin; Han-Sun Chiang; Yi-No Wu
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.